As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab plus chemotherapy as a neo-adjuvant therapy in patients with previously untreated locally advanced non-metastatic triple negative breast cancer. I am writing to advise that following an update from the company, NICE has rescheduled the appraisal and it is expected to begin in mid-July 2019.